阿替维啶在无症状人类免疫缺陷病毒感染个体中的安全性、耐受性及疗效。
Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals.
作者信息
Been-Tiktak A M, Williams I, Vrehen H M, Richens J, Aldam D, van Loon A M, Loveday C, Boucher C A, Ward P, Weller I V, Borleffs J C
机构信息
Department of Internal Medicine, University Hospital Utrecht, The Netherlands.
出版信息
Antimicrob Agents Chemother. 1996 Nov;40(11):2664-8. doi: 10.1128/AAC.40.11.2664.
Abstract
Atevirdine is a nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). In this study we investigated the effect of atevirdine in asymptomatic antiretroviral naive HIV-infected patients with CD4+ cell counts of between 200 and 750 cells per mm3. Patients were randomized to receive 600 mg of atevirdine (n = 15) or a placebo (n = 15) three times a day for 12 weeks. There was no statistically significant effect of atevirdine on viral loads (HIV p24 antigen and HIV-1 RNA levels by PCR) or CD4+ cell counts. The data do not support the use of atevirdine as a monotherapy in the treatment of HIV-infected patients.
摘要
阿特韦定是一种针对人类免疫缺陷病毒1型（HIV-1）的非核苷类逆转录酶抑制剂。在本研究中，我们调查了阿特韦定对无症状且未接受过抗逆转录病毒治疗、CD4+细胞计数在每立方毫米200至750个之间的HIV感染患者的影响。患者被随机分为两组，一组每天三次服用600毫克阿特韦定（n = 15），另一组每天三次服用安慰剂（n = 15），为期12周。阿特韦定对病毒载量（通过PCR检测的HIV p24抗原和HIV-1 RNA水平）或CD4+细胞计数没有统计学上的显著影响。这些数据不支持将阿特韦定作为单一疗法用于治疗HIV感染患者。
相似文献
1
Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals.阿替维啶在无症状人类免疫缺陷病毒感染个体中的安全性、耐受性及疗效。
Antimicrob Agents Chemother. 1996 Nov;40(11):2664-8. doi: 10.1128/AAC.40.11.2664.
2
Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team.非核苷类逆转录酶抑制剂阿替维定与齐多夫定联合用于1型人类免疫缺陷病毒感染的I期研究。美国国立过敏与传染病研究所艾滋病临床试验组199研究团队
J Infect Dis. 1995 Feb;171(2):297-304. doi: 10.1093/infdis/171.2.297.
3
Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients.甲磺酸阿替维啶（U - 87201E）单药治疗HIV - 1感染患者的I期研究。
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Oct 1;19(2):135-44. doi: 10.1097/00042560-199810010-00006.
4
Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients.甲磺酸阿替维啶（U-87201E）在无症状人类免疫缺陷病毒感染患者中的安全性、耐受性及药代动力学
Antimicrob Agents Chemother. 1995 Mar;39(3):602-7. doi: 10.1128/AAC.39.3.602.
5
Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.去羟肌苷降低了人类免疫缺陷病毒感染患者中阿替维啶的吸收。
Antimicrob Agents Chemother. 1996 Mar;40(3):767-71. doi: 10.1128/AAC.40.3.767.
6
The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials.对未接受过抗逆转录病毒治疗的受试者使用拉米夫定/齐多夫定联合治疗：北美（NUCA 3001）和欧洲（NUCB 3001）试验综述。
AIDS. 1996 Dec;10 Suppl 5:S11-9. doi: 10.1097/00002030-199612005-00003.
7
Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.甲磺酸阿替维啶针对HIV感染患者的浓度靶向I期试验：剂量要求和药代动力学研究。ACTG 187和199研究团队。
Antiviral Res. 2000 Jan;45(1):47-58. doi: 10.1016/s0166-3542(99)00073-x.
8
The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.高剂量沙奎那韦对HIV感染患者病毒载量和CD4 + T细胞计数的影响。
Ann Intern Med. 1996 Jun 15;124(12):1039-50. doi: 10.7326/0003-4819-124-12-199606150-00003.
9
10
Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.维帕他韦复方制剂联合优化治疗方案治疗经治患者：VICTOR-E1 期 2 临床试验 48 周结果。
J Infect Dis. 2010 Feb 15;201(4):590-9. doi: 10.1086/650342.
本文引用的文献
1
How to deal with regression to the mean in intervention studies.如何在干预研究中处理均值回归问题。
Lancet. 1996 Jan 27;347(8996):241-3. doi: 10.1016/s0140-6736(96)90410-9.
2
Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group.用于测定临床1型人类免疫缺陷病毒分离株药物敏感性的标准化外周血单核细胞培养试验。RV - 43研究组，艾滋病临床试验组病毒学委员会耐药性工作组。
Antimicrob Agents Chemother. 1993 May;37(5):1095-101. doi: 10.1128/AAC.37.5.1095.
3
Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents.人类免疫缺陷病毒临床分离株对抗逆转录病毒药物的耐药性。
Antimicrob Agents Chemother. 1993 Jun;37(6):1207-13. doi: 10.1128/AAC.37.6.1207.
4
Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients.甲磺酸阿替维啶（U-87201E）在无症状人类免疫缺陷病毒感染患者中的安全性、耐受性及药代动力学
Antimicrob Agents Chemother. 1995 Mar;39(3):602-7. doi: 10.1128/AAC.39.3.602.
5
A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group.HIV-1逆转录酶非核苷抑制剂L-697,661的短期临床评估。L-697,661研究小组
N Engl J Med. 1993 Oct 7;329(15):1065-72. doi: 10.1056/NEJM199310073291502.
6
Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
J Infect Dis. 1993 Aug;168(2):318-26. doi: 10.1093/infdis/168.2.318.
7
A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.对双（杂芳基）哌嗪耐药的1型人类免疫缺陷病毒逆转录酶中的一种突变，该突变使病毒对其他非核苷抑制剂的敏感性增加。
Proc Natl Acad Sci U S A. 1993 May 15;90(10):4713-7. doi: 10.1073/pnas.90.10.4713.
8
Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor.
J Infect Dis. 1995 May;171(5):1159-65. doi: 10.1093/infdis/171.5.1159.
9
Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.非核苷类抑制剂对HIV-1逆转录酶的抑制机制。
Science. 1995 Feb 17;267(5200):988-93. doi: 10.1126/science.7532321.
10
Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team.非核苷类逆转录酶抑制剂阿替维定与齐多夫定联合用于1型人类免疫缺陷病毒感染的I期研究。美国国立过敏与传染病研究所艾滋病临床试验组199研究团队
J Infect Dis. 1995 Feb;171(2):297-304. doi: 10.1093/infdis/171.2.297.
Zotero 插件